PTO/SB/68 (04-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION	UNDER 37 CFR 1.14(e)					
In re Application	n of					
RECEIVED MAR 0 4 2002 File Information Unit Application Num 68/72/44 Art Unit //64	1					
·	Paper No.					
Assistant Commissioner for Patents Washington, DC 20231						
1. Thereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)						
(A) referred to in:	4.3					
United States Patent Application Publication No63/6						
United States Patent Number	, column, line, or					
an International Application which was filed on or after Nover	mber 29, 2000 and which					
designates the United States, WIPO Pub. No.	, page, line					
(B) referred to in an application that is open to public inspection						
						
1.14(e)(2)(i), i.e., Application No, paper No, page, line						
2. I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.						
Hanny 1)un	2-9-02					
Signature	Date .					
He was no	707 770 1107 ONLY					
	FOR PTO USE ONLY					
Typed or printed name	Approved by:					
	(initials)					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



(12) United States Patent Pinsky et al.

(10) Patent No.:

US 6,316,403 B1

(45) Date of Patent:

Nov. 13, 2001

METHODS FOR TREATING AN ISCHEMIC DISORDER AND IMPROVING STROKE **OUTCOME**

(75) Inventors: David J. Pinsky, Riverdale; David

Stern, Great Neck, both of NY (US); Ann Marie Schmidt, Franklin Lakes; Eric A. Rose, Tenafly, both of NJ (US); E. Sander Connolly, New York; Robert A. Solomon, Palisades, both of NY (US); Charles J. Prestigiacomo,

Teaneck, NJ (US)

(73) Assignce: The Trustees of Columbia University

in the City of New York, New York,

NY (US)

(*) Notice:

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.:

09/269,426

(22) PCT Filed:

Sep. 25, 1997

(86) PCT No.:

PCT/US97/17229

§ 371 Date:

Jun. 25, 1999

§ 102(e) Date: Jun. 25, 1999

(87) PCT Pub. No.: WO98/13058

PCT Pub. Date: Apr. 2, 1998

Related U.S. Application Data

(63)	Continuation-in-part of application No. 08/721,447, filed on Sep. 27, 1996, now abandoned.
	Sep. 27, 1996, now abandoned.

(51)) Int.	Cl. ⁷		A61K	38/00
------	--------	------------------	--	------	-------

U.S. Cl. 514/2; 514/21

Field of Search 514/23, 20, 2,

(56)References Cited

U.S. PATENT DOCUMENTS

4,711,848 12/1987 Insley et al. 435/91

FOREIGN PATENT DOCUMENTS

2141641 8/1995 (CA).

OTHER PUBLICATIONS

Tijburg, et al. (1990) Activation of the Coagulation Mechanism on Tumor Necrosis Factor-stimulated Cultured Endothelial Cells and Their Extracellular Matrix, J. Biol. Chem. 266:12067-12074.

Benedict, C.R., et al., 1994, Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Texas Heat Institute Journal 21:86-90.

Benedict et al. (1991) Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model, J. Clin. Invest. 88, 1760-1765. Brandstetter et al. (PNAS 92:9796-800, 1995).

Bronner et al. (1995) Primary prevention of stroke, New Eng. J. Med. 333, 1392-1400.

Brown and Piantadosi (1992) Recovery of energy metabolism in rat after carbon monoxide hypoxia, J. Clin. Invest. 89, 666-672.

Carlos and Harlan (1994) Leukocyte-endothelial adhesion molecules, Blood 24, 2068-2101.

Connolly et al. (1996) Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion, J. Clin. Invest. 97, 209-216.

Connolly et al. (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia, Neurosurgery 38, 523-532.

Dawson and Snyder (1994) Gases as biological messengers: nitric oxide and carbon monoxide in the brain, J. Neurosci. 14, 5147-5159.

Fassbender et al. (1995) Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke, Stroke 26, 1361-1364.

Holdright, D., et al., 1994, Comparison of the effect of heparin and aspiring versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina J. Am. Coll. Cardiol. 24:39-45.

Ishimaru et al. (1991) Effects of successive carbon monoxide exposures on delayed neuronal death in mice under the maintenance of normal body temperature, Biochem. Biophys. Res. Commun. 179, 836-840.

Jerome et al. (1994) P-selectin and ICAM-1 dependent adherence reactions: role in the genesis of postichemic no-reflow, Am. J. Physiol. 266, H1316-H1321.

Kim et al. (1995) Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks, J. Neurol. Sci. 128, 45-50.

Kochaneck and Hallenbeck (1992) Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke, Stroke 23, 1367-1379.

Mayevsky et al. (1995) Multiparametric monitoring of the awake brain exposed to carbon monoxide, J. Appl. Physiol. 78, 1188-1196.

Okada et al. (1994) P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion, Stroke 25, 202-211.

(List continued on next page.)

Primary Examiner-Elli Peselev

(74) Attorney, Agent, or Firm-John P. White; Cooper & Dunham LLP

ABSTRACT

The present invention provides for a method of treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

19 Claims, 60 Drawing Sheets